BACE1 and Alzheimer disease: Compound 4 showed strong BACE1 inhibition (IC50 = 69 nM), and compound 3 exhibited strong AChE inhibition (IC50 = 1.93 μM), which was supported by molecular docking, and highlighted their potential as anti-AD therapeutics [94].